Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

348P - Malignant melanoma: A study of clinical profiles and treatment outcomes in Indian patients

Date

23 Nov 2019

Session

Poster display session

Topics

Tumour Site

Melanoma

Presenters

Sorun Shishak

Citation

Annals of Oncology (2019) 30 (suppl_9): ix115-ix117. 10.1093/annonc/mdz429

Authors

S.A. Shishak1, S. Rastogi2, R. Pandey3, A. Barwad4, E. Dhamija5, A. Aggarwal6, K. Kalra7, S.A. Shamim8, M. Parisa2

Author affiliations

  • 1 Radiation Oncology, AIIMS - All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 2 Medical Oncology, AIIMS - All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 3 Department Of Radiation Oncology, AIIMS - All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 4 Department Of Pathology, AIIMS - All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 5 Radiology, AIIMS - All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 6 Radiation Oncology, National Cancer Institute-AIIMS,Jhajjar, 124105 - Haryana/IN
  • 7 Medical Oncology Department, AIIMS - All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 8 Nuclear Medicine, AIIMS - All India Institute of Medical Sciences, 110029 - New Delhi/IN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 348P

Background

Malignant melanoma is an extremely rare malignancy in the Indian subcontinent and South east Asia. Its already known that Asian countries have different clinical presentation of melanoma. It would be interesting to know the epidemiology and outcome of advanced disease in Indian patients.

Methods

We retrospectively analysed patients with malignant melanoma who were registered in Medical Oncology clinic at AIIMS, New Delhi between January 2016 and July 2019. We used SPSS version 23 for analysis. Immunotherapy used was single agent Nivolumab as Ipilimumab is unavailable.

Results

Total of 93 patients (57 males, 36 females) were registered in the study. Median age was 53 (range, 25 to 85 years), with the commonest primary sites being anorectal (n = 23) and foot (n = 23), followed by eye (n = 15), head and neck (n = 12), thigh (n = 9), others (n = 11) respectively. The commonest sites of metastasis were lymph nodes (n = 54, 58.1%), lung (n = 45,48.4%), liver(n = 33,35.5%) and bone(n = 25,26.9%).The median sites of metastasis was two (range 1-5). Most patients had ECOG PS 1-2 (n = 77, 82.8%). Majority of the patients (n = 80,86%) had metastasis.Out of 93 patients, 39(42%) received chemotherapy in first line, 16 (17.3%) received Immunotherapy, 13 (13.9%) underwent surgery and best supportive care was offered to 25 (26.8%) patients. The chemotherapy used were dacarbazine (n = 27), nabpaclitaxel (n = 6) and others (n = 6). Among patients who received chemo, median number of cycles was 5 (range,1-15) and response assessment revealed progressive disease in 17 patients, stable disease in 4 patients, partial response in one patient, and remaining 16 patients defaulted and were not evaluable. Among patients who received Single agent Nivolumab, the median number of cycles was 5 (range,2-15) and response showed progressive disease in all patients, except one. Median follow up was 18 months and median PFS was 3 months.

Conclusions

This study shows that the site of melanoma in Indian patients is different as compared to western patients with higher number of anorectal, mucosal and acral melanoma. Immunotherapy was feasible for only a fraction of patients in view of exorbitant cost. Non availability of BRAF therapies and Ipilimumab is of great concern in view of poor outcomes.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.